DOCSLIB.ORG

In Iron Utensils.' Overload, in the Original Hypothesis,' Also Hereditary

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
In Iron Utensils.' Overload, in the Original Hypothesis,' Also Hereditary Letters 937 Hepatocellular carcinoma and African We entirely support the authors in their hepatocellular carcinoma (HCC) and the tox- iron overload urge that prospective studies should be icity of iron overload in Africa. undertaken to examine the possible role of High quality cancer epidemiological data EDITOR,-Gangaidzo and Gordeuk (Gut African overload in the pathogenesis of HCC. are difficult to come by in Africa. With regard 1995; 37: 727-30) postulate that iron over- However, at the village level, in the requisite to the estimate ofDrs Walker and Segal offive load may be a risk factor for hepatocellular studies, major difficulties will be encountered admissions for HCC per 100 000 population Gut: first published as 10.1136/gut.38.6.937-a on 1 June 1996. Downloaded from carcinoma (HCC) - a subject of obvious regarding participation, especially regarding annually in rural South Africa, we note that interest to workers in Africa. It is especially so blood taking and the fear of AIDS. A compli- hospital based studies may be unreliable to one of us (AW) who, originally, in 1953, cating factor for HCC, as Kew and associates9 estimates of countrywide incidence rates.' propounded the iron overload hypothesis. have shown, is that the infection rate of HBV, HCC is a common and important condition This sought to explain the abnormal iron an important aetiological factor, varies not in Africa. At least one authority has observed, deposition (siderosis) present in many only from region to region, but from village to with regard to HCC, that 'some of the docu- Africans, caused by a high adventitious intake village. Additionally, there will be the usual mented incidences are almost certainly of the element arising from food preparation difficulties in seeking to resolve whether iron underestimates, perhaps by as much as 50 in iron utensils.' overload, if implicated, is a causative or an percent in some countries'.2 A contemporary In comment, firstly, the above authors state associated factor. Not least of perplexities textbook of gastroenterology in the tropics that HCC is probably the commonest malig- is the situation whereby a given parameter, offers an adjusted rate for HCC of 113 per nancy occurring in men worldwide. Actually for example, serum ferritin concentration, 100 000 per annum in Shangaan men inhab- it ranks eighth in numerical importance on a can have a differing significance according to iting the border areas of Mozambique, worldwide basis, accounting for 5-3% of new the context. As a recent example of this Zimbabwe, and South Africa.2 In Harare, cancers in men and 2-6% in women.2 phenomenon, at Belfast and Toulouse, there Zimbabwe, HCC is the most common malig- Next, it is insufficiently appreciated that its is the same average serum cholesterol value nancy in men in the 1990s (Harare Cancer incidence in men in Africa is highly variable, but a fourfold difference in mortality from Registry, 1995). In the internal medicine ranging from 47-9 per 100 000 world popula- coronary heart disease.'0 wards of one of us (ITG) at Harare Central tion, in Mali,3 to 7-5 in Uganda,4 and 6.4 in Finally, should iron overload be meaning- Hospital, HCC was the most common cancer South Africa.5 In agreement with the latter, fully incriminated, the authors say 'it is diagnosis in men in 1993-1994 and recently, in three rural widely separated eminently preventable through changing the accounted for 3-2% of admissions. Among hospitals, responsible for the needs of about practices of preparation and consumption of those of us who regularly provide medical 400 000 Africans, we found an average offive traditional beer, and it is treatable by phlebot- care to rural Africans (constituting more than admissions of men for HCC per 100 000 omy therapy to remove iron from the body'. 80% of the Zimbabwean population), there is annually. Interestingly, the latter rates are In our view, both ofthe suggested procedures, general agreement that HCC represents a much the same as those of Afro-Americans, in the rural context, are non-starters. major health problem. We have seen 'few 50-6.6 per 100 000.3 The citing of 100 cases To reiterate, while we are unconvinced of more depressing tasks than caring for a per 100 000 in Mozambique is inapposite as the clinical importance of iron overload, the patient with this particular malignancy, no current study ofthe painstaking type made issue must be resolved - that is, whether it is and there is no satisfactory treatment'.3 in Uganda,4 has been pursued in or is not of public health significance within The question of whether iron overload in Mozambique - a country at war for 20 years. the context of impoverished Africa. Africa is 'noxious', seems to recapitulate the We know of no present day excessively high A R P WALKER discussion of 30 years ago about whether iron rates for HCC in African countries south of Human Biochemistry Research Unit, overload is damaging in people of European Department of Tropical Diseases, origin with hereditary haemochromatosis. As the Equator. School ofPathology ofthe of iron we learn more about states of excess iron, it is Turning now to the noxiousness University ofthe Witwatersrand, and the http://gut.bmj.com/ overload, in the original hypothesis,' also South African Institutefor Medical Research, our opinion that the weight ofevidence points on 296 Johannesburg, to the conclusion that iron overload of what- in a subsequent local study based South Africa postmortem examinations at Baragwanath ever cause (HLA linked hemochromatosis, Hospital, Soweto, Johannesburg,6 the patho- ISIDOR SEGAL transfusions, ineffective erythropoiesis, or Gastroenterology Unit, dietary iron in Africa) is potentially toxic, genicity of iron overload was doubted, for no Baragwanath Hospital high constant correlation was found between the and University ofthe Witwatersrand, and that medical practitioners are obligated to degrees of fibrosis and cirrhosis and the Johannesburg, work to prevent and treat iron overload in amount ofiron pigment in the liver. However, South Africa their patients.4 In a series of careful patholog- ical studies 35 years ago, Professor T H on September 28, 2021 by guest. Protected copyright. later, at the same hospital, as recently detailed 1 Walker ARP, Arvidsson UB. Iron 'overload' in by Lynch,7 associations were reported of the South African Bantu. Trans R Soc Trop Bothwell and colleagues at the University siderosis with osteoporosis, diabetes, oeso- Med Hyg 1953; 47: 536-48. of the Witwatersrand provided convincing 2 Tomatis L. Cancer: causes, occurrence and control. evidence that dietary iron overload directly phageal cancer, and heart failure. The find- International Agency for Research on Cancer, ings in these studies, however, made over 20 IARC Scientific Publications No 100. Lyon: causes cirrhosis.5-7 Interestingly, in 1960 years ago, have not been currently confirmed. World Health Organization, 1990: 59. Bothwell reported that in Africans the hepatic More to the point, over the decades, no 3 Parkin BM, Muir CS, Whelan SL, et al. Cancer iron threshold above which portal fibrosis and incidence infive continents. Vol 6. Lyon: IARC, are to be is a concen- attempt has been made at the village level to 1992: 930. cirrhosis likely present learn whether iron overload contributes 4 Wabinga HR, Parkin DM, Wabwire-Mangen F, tration of 360 ,umol/g dry weight5 (normal is and that Mugerwa JW. Cancer in Kampala, Uganda, in less than 30 ,umol/g dry weight). Twenty six significantly to morbidity mortality; in the era of is, is it disadvantageous to 1 per 100, or 1 per 1989-91: changes in incidence years later Dr L Powell's group in Australia AIDS. Int_J Cancer 1993; 54: 26-36. for 1000? 5 Sitas F, Pacella R. Cancer regist"y ofSouth Africa, reported an almost identical threshold In an investigation made in 1985 by 1989. Johannesburg: South African Institute hepatic damage among white subjects with Gordeuk et a18 in Zimbabwe, it was estimated for Medical Research, 1994: 33. hereditary hemochromatosis.8 Support for the 6 Higginson J, Gerritsen Th, Walker ARP. African iron overload that there were about 80 000 cases of severe Siderosis in the Bantu of Southern Africa. association between iron overload. In the same year, it was stated Am JPathology 1953; XXIX: 779-815. and cirrhosis is provided by a study con- that in that country there were 14 587 cases of 7 Lynch SR. Iron overload: prevalence and impact ducted in the late 1980s at a mission hospital on health. Nutr Rev 1995; 53: 255-60. in Swaziland: nine of 29 consecutive adults malaria, 2956 of tuberculosis, and 144 of 8 Gordeuk VR, Boyd RD, Brittenham GM. cholera. Surely, were iron overload as patho- Dietary iron overload persists in rural sub- undergoing diagnostic liver biopsy had gnomonic as is conjectured, there should be a Saharan Africa. Lancet 1986; i: 1310-3. hepatic iron concentrations over 360 ,ug/g plethora of evidence incriminating it. This 9 Kew MC. Chronic hepatitis B virus infection dry weight and seven of these subjects (78%) and hepatocellular carcinoma in Africa. SAfrJ fibrosis or cirrhosis on does not seem to be the case. Sci 1992; 88: 524-8. had either portal Gangaidzo and Gordeuk regret that in 10 Evans AE, Ruidavets J-B, McCrum EE, et al. histological examination.9 Africa, only about half of the cases of HCC Autres pays, autres coeurs? Dietary patterns, Two recent studies that we have conducted risk factors and ischaemic heart disease in examine the noxiousness of dietary iron over- are explicable on the basis of HBV infection. Belfast and Toulouse. Q Jf Med 1995; 88: It must be recognised that apart from the 469-77. load in data sets that span the historical spec- cause and effect of classic deficiency diseases, trum of this disease.
Load more

Recommended publications
  • Primary Liver Cancer: Epidemiological And
    PRIMARY LIVER CANCER: EPIDEMIOLOGICAL AND BIOMARKER DISCOVERY STUDIES Nimzing Gwamzhi Ladep Imperial College London Department of Medicine December 2013 Thesis submitted for Doctor of Philosophy 1 THESIS ABSTRACT With previous reports indicating changes in mortality, risk factors and management of primary liver cancer (PLC), evaluation of current trends in the incidence and mortality rates was indicated. Late diagnosis has been implicated to be a major contributor to the high fatality rates of PLC. This work aimed at: studying trends of PLC by subcategories globally in general, and in England and Wales, in particular; investigating liver-related morbidities of HIV infected patients in an African setting; and discovering urinary biomarkers of hepatocellular carcinoma. The World Health Organisation (WHO) and Small Area Health Statistics Unit (SAHSU) databases were interrogated respectively, in order to achieve the first aim. The second aim was achieved through utilisation of databases of an African-based HIV treatment programme- AIDS Prevention Initiative in Nigeria (APIN), located in Jos, Nigeria. The European Union-funded Prevention of Liver Fibrosis and Cancer in Africa (PROLIFICA) case-control study in three West African countries was the platform through which urinary metabolic profiling was accomplished. Proton nuclear magnetic resonance spectroscopy (NMR) and parallel ultra-performance liquid chromatography mass spectrometry (UPLC-MS) were used for biomarker discovery studies. Mortality rates of intrahepatic bile duct carcinoma (IHBD) increased in all countries that were studied. Misclassification of hilar cholangiocarcinoma accounted for only a small increase in the rate of IHBD in England and Wales. With over 90% screening rate for viral hepatitides, the rates of hepatitis B (HBV), hepatitis C (HCV) and 2 HBV/HCV in HIV-infected patients in the APIN programme were 17.8%, 11.3% and 2.5% respectively.
    [Show full text]
  • Nutrient Deficiency and Drug Induced Cardiac Injury and Dysfunction
    Editorial Preface to Hearts Special Issue “Nutrient Deficiency and Drug Induced Cardiac Injury and Dysfunction” I. Tong Mak * and Jay H. Kramer * Department of Biochemistry and Molecular Medicine, The George Washington University Medical Center, Washington DC, WA 20037, USA * Correspondence: [email protected] (I.T.M.); [email protected] (J.H.K.) Received: 30 October 2020; Accepted: 1 November 2020; Published: 3 November 2020 Keywords: cardiac injury/contractile dysfunction; micronutrient deficiency; macromineral deficiency or imbalance; impact by cardiovascular and/or anti-cancer drugs; systemic inflammation; oxidative/nitrosative stress; antioxidant defenses; supplement and/or pathway interventions Cardiac injury manifested as either systolic or diastolic dysfunction is considered an important preceding stage that leads to or is associated with eventual heart failure (HF). Due to shifts in global age distribution, as well as general population growth, HF is the most rapidly growing public health issue, with an estimated prevalence of approximately 38 million individuals globally, and it is associated with considerably high mortality, morbidity, and hospitalization rates [1]. According to the US Center for Disease Control and The American Heart Association, there were approximately 6.2 million adults suffering from heart failure in the United States from 2013 to 2016, and heart failure was listed on nearly 380,000 death certificates in 2018 [2]. Left ventricular systolic heart failure means that the heart is not contracting well during heartbeats, whereas left ventricular diastolic failure indicates the heart is not able to relax normally between beats. Both types of left-sided heart failure may lead to right-sided failure. There have been an increasing number of studies recognizing that the deficiency and/or imbalance of certain essential micronutrients, vitamins, and macrominerals may be involved in the pathogenesis of cardiomyopathy/cardiac injury/contractile dysfunction.
    [Show full text]
  • Secondary Hemochromatosis As a Result of Acute Transfusion-Induced Iron Overload in a Burn Patient Michael Amatto1 and Hernish Acharya2*
    Amatto and Acharya Burns & Trauma (2016) 4:10 DOI 10.1186/s41038-016-0034-z CASE REPORT Open Access Secondary hemochromatosis as a result of acute transfusion-induced iron overload in a burn patient Michael Amatto1 and Hernish Acharya2* Abstract Background: Red blood cell transfusions are critical in burn management. The subsequent iron overload that can occur from this treatment can lead to secondary hemochromatosis with multi-organ damage. Case Presentation: While well recognized in patients receiving chronic transfusions, we present a case outlining the acute development of hemochromatosis secondary to multiple transfusions in a burn patient. Conclusions: Simple screening laboratory measures and treatment options exist which may significantly reduce morbidity; thus, we believe awareness of secondary hemochromatosis in those treating burn patients is critical. Keywords: Secondary hemochromatosis, Transfusion, Iron overload, Burn patients Background of parental iron or RBC transfusions, neonatal iron over- Acute and chronic treatment of the severely burned indi- load, aceruloplasminemia, and African iron overload [6, 7]. vidual is often complex due to many physical and psycho- Hemochromatosis is a disease characterized by iron logical factors [1, 2]. Resuscitation involving packed red accumulation in tissues. Initial symptoms and signs in- blood cell (RBC) transfusion is often essential [3]. How- clude skin pigmentation, fatigue, erectile dysfunction, ever, RBC transfusion carries potential risks including and arthralgia while later stages of the disease result in hemolytic reactions and infections, as well as other com- cardiomyopathy, diabetes mellitus, hypogonadism, hypo- plications that are often overlooked such as iron overload pituitarism, and hypoparathyroidism, as well as liver fi- [4, 5]. Each unit of RBCs contains 200–250 mg of iron, brosis and cirrhosis which can lead to hepatocellular and with no physiologic excretion mechanism, multiple carcinoma [6].
    [Show full text]
  • Orphanet Report Series Rare Diseases Collection
    Marche des Maladies Rares – Alliance Maladies Rares Orphanet Report Series Rare Diseases collection DecemberOctober 2013 2009 List of rare diseases and synonyms Listed in alphabetical order www.orpha.net 20102206 Rare diseases listed in alphabetical order ORPHA ORPHA ORPHA Disease name Disease name Disease name Number Number Number 289157 1-alpha-hydroxylase deficiency 309127 3-hydroxyacyl-CoA dehydrogenase 228384 5q14.3 microdeletion syndrome deficiency 293948 1p21.3 microdeletion syndrome 314655 5q31.3 microdeletion syndrome 939 3-hydroxyisobutyric aciduria 1606 1p36 deletion syndrome 228415 5q35 microduplication syndrome 2616 3M syndrome 250989 1q21.1 microdeletion syndrome 96125 6p subtelomeric deletion syndrome 2616 3-M syndrome 250994 1q21.1 microduplication syndrome 251046 6p22 microdeletion syndrome 293843 3MC syndrome 250999 1q41q42 microdeletion syndrome 96125 6p25 microdeletion syndrome 6 3-methylcrotonylglycinuria 250999 1q41-q42 microdeletion syndrome 99135 6-phosphogluconate dehydrogenase 67046 3-methylglutaconic aciduria type 1 deficiency 238769 1q44 microdeletion syndrome 111 3-methylglutaconic aciduria type 2 13 6-pyruvoyl-tetrahydropterin synthase 976 2,8 dihydroxyadenine urolithiasis deficiency 67047 3-methylglutaconic aciduria type 3 869 2A syndrome 75857 6q terminal deletion 67048 3-methylglutaconic aciduria type 4 79154 2-aminoadipic 2-oxoadipic aciduria 171829 6q16 deletion syndrome 66634 3-methylglutaconic aciduria type 5 19 2-hydroxyglutaric acidemia 251056 6q25 microdeletion syndrome 352328 3-methylglutaconic
    [Show full text]
  • Essential Trace Elements in Human Health: a Physician's View
    Margarita G. Skalnaya, Anatoly V. Skalny ESSENTIAL TRACE ELEMENTS IN HUMAN HEALTH: A PHYSICIAN'S VIEW Reviewers: Philippe Collery, M.D., Ph.D. Ivan V. Radysh, M.D., Ph.D., D.Sc. Tomsk Publishing House of Tomsk State University 2018 2 Essential trace elements in human health UDK 612:577.1 LBC 52.57 S66 Skalnaya Margarita G., Skalny Anatoly V. S66 Essential trace elements in human health: a physician's view. – Tomsk : Publishing House of Tomsk State University, 2018. – 224 p. ISBN 978-5-94621-683-8 Disturbances in trace element homeostasis may result in the development of pathologic states and diseases. The most characteristic patterns of a modern human being are deficiency of essential and excess of toxic trace elements. Such a deficiency frequently occurs due to insufficient trace element content in diets or increased requirements of an organism. All these changes of trace element homeostasis form an individual trace element portrait of a person. Consequently, impaired balance of every trace element should be analyzed in the view of other patterns of trace element portrait. Only personalized approach to diagnosis can meet these requirements and result in successful treatment. Effective management and timely diagnosis of trace element deficiency and toxicity may occur only in the case of adequate assessment of trace element status of every individual based on recent data on trace element metabolism. Therefore, the most recent basic data on participation of essential trace elements in physiological processes, metabolism, routes and volumes of entering to the body, relation to various diseases, medical applications with a special focus on iron (Fe), copper (Cu), manganese (Mn), zinc (Zn), selenium (Se), iodine (I), cobalt (Co), chromium, and molybdenum (Mo) are reviewed.
    [Show full text]
  • Genetic Disorder
    Genetic disorder Single gene disorder Prevalence of some single gene disorders[citation needed] A single gene disorder is the result of a single mutated gene. Disorder Prevalence (approximate) There are estimated to be over 4000 human diseases caused Autosomal dominant by single gene defects. Single gene disorders can be passed Familial hypercholesterolemia 1 in 500 on to subsequent generations in several ways. Genomic Polycystic kidney disease 1 in 1250 imprinting and uniparental disomy, however, may affect Hereditary spherocytosis 1 in 5,000 inheritance patterns. The divisions between recessive [2] Marfan syndrome 1 in 4,000 and dominant types are not "hard and fast" although the [3] Huntington disease 1 in 15,000 divisions between autosomal and X-linked types are (since Autosomal recessive the latter types are distinguished purely based on 1 in 625 the chromosomal location of Sickle cell anemia the gene). For example, (African Americans) achondroplasia is typically 1 in 2,000 considered a dominant Cystic fibrosis disorder, but children with two (Caucasians) genes for achondroplasia have a severe skeletal disorder that 1 in 3,000 Tay-Sachs disease achondroplasics could be (American Jews) viewed as carriers of. Sickle- cell anemia is also considered a Phenylketonuria 1 in 12,000 recessive condition, but heterozygous carriers have Mucopolysaccharidoses 1 in 25,000 increased immunity to malaria in early childhood, which could Glycogen storage diseases 1 in 50,000 be described as a related [citation needed] dominant condition. Galactosemia
    [Show full text]
  • Diseases of the Liver and Biliary System
    Diseases of the Liver and Biliary System SHEILA SHERLOCK DBE, FRS MD (Edin.), Hon. DSc (Edin., New York, Yale), Hon. MD (Cambridge, Dublin, Leuven, Lisbon, Mainz, Oslo, Padua, Toronto), Hon. LLD (Aberd.), FRCP, FRCPE, FRACP, Hon. FRCCP, Hon. FRCPI, Hon. FACP Professor of Medicine, Royal Free and University College Medical School University College London, London JAMES DOOLEY BSc, MD, FRCP Reader and Honorary Consultant in Medicine, Royal Free and University College Medical School, University College London, London ELEVENTH EDITION Blackwell Science DISEASES OF THE LIVER AND BILIARY SYSTEM Diseases of the Liver and Biliary System SHEILA SHERLOCK DBE, FRS MD (Edin.), Hon. DSc (Edin., New York, Yale), Hon. MD (Cambridge, Dublin, Leuven, Lisbon, Mainz, Oslo, Padua, Toronto), Hon. LLD (Aberd.), FRCP, FRCPE, FRACP, Hon. FRCCP, Hon. FRCPI, Hon. FACP Professor of Medicine, Royal Free and University College Medical School University College London, London JAMES DOOLEY BSc, MD, FRCP Reader and Honorary Consultant in Medicine, Royal Free and University College Medical School, University College London, London ELEVENTH EDITION Blackwell Science © 1963, 1968, 1975, 1981, 1985, 1989, 1993, 1997, 2002 by Blackwell Science Ltd a Blackwell Publishing Company Editorial Offices: Osney Mead, Oxford OX2 0EL, UK Tel: +44 (0)1865 206206 108 Cowley Road, Oxford OX4 1JF, UK Tel: +44 (0)1865 791100 Blackwell Publishing USA, 350 Main Street, Malden, MA 02148-5018, USA Tel: +1 781 388 8250 Iowa State Press, a Blackwell Publishing Company, 2121 State Avenue, Ames,
    [Show full text]
  • Diagnosis and Treatment of Wilson Disease: an Update
    AASLD PRACTICE GUIDELINES Diagnosis and Treatment of Wilson Disease: An Update Eve A. Roberts1 and Michael L. Schilsky2 This guideline has been approved by the American Asso- efit versus risk) and level (assessing strength or certainty) ciation for the Study of Liver Diseases (AASLD) and rep- of evidence to be assigned and reported with each recom- resents the position of the association. mendation (Table 1, adapted from the American College of Cardiology and the American Heart Association Prac- Preamble tice Guidelines3,4). These recommendations provide a data-supported ap- proach to the diagnosis and treatment of patients with Introduction Wilson disease. They are based on the following: (1) for- Copper is an essential metal that is an important cofac- mal review and analysis of the recently-published world tor for many proteins. The average diet provides substan- literature on the topic including Medline search; (2) tial amounts of copper, typically 2-5 mg/day; the American College of Physicians Manual for Assessing recommended intake is 0.9 mg/day. Most dietary copper 1 Health Practices and Designing Practice Guidelines ; (3) ends up being excreted. Copper is absorbed by entero- guideline policies, including the AASLD Policy on the cytes mainly in the duodenum and proximal small intes- Development and Use of Practice Guidelines and the tine and transported in the portal circulation in American Gastroenterological Association Policy State- association with albumin and the amino acid histidine to 2 ment on Guidelines ; (4) the experience of the authors in the liver, where it is avidly removed from the circulation. the specified topic.
    [Show full text]
  • Practical Management of Iron Overload Disorder (IOD) in Black Rhinoceros (BR; Diceros Bicornis)
    animals Review Practical Management of Iron Overload Disorder (IOD) in Black Rhinoceros (BR; Diceros bicornis) Kathleen E. Sullivan, Natalie D. Mylniczenko , Steven E. Nelson Jr. , Brandy Coffin and Shana R. Lavin * Disney’s Animal Kingdom®, Animals, Science and Environment, Bay Lake, FL 32830, USA; [email protected] (K.E.S.); [email protected] (N.D.M.); [email protected] (S.E.N.J.); Brandy.Coffi[email protected] (B.C.) * Correspondence: [email protected]; Tel.: +1-407-938-1572 Received: 29 September 2020; Accepted: 26 October 2020; Published: 29 October 2020 Simple Summary: Black rhinoceros under human care are predisposed to Iron Overload Disorder that is unlike the hereditary condition seen in humans. We aim to address the black rhino caretaker community at multiple perspectives (keeper, curator, veterinarian, nutritionist, veterinary technician, and researcher) to describe approaches to Iron Overload Disorder in black rhinos and share learnings. This report includes sections on (1) background on how iron functions in comparative species and how Iron Overload Disorder appears to work in black rhinos, (2) practical recommendations for known diagnostics, (3) a brief review of current investigations on inflammatory and other potential biomarkers, (4) nutrition knowledge and advice as prevention, and (5) an overview of treatment options including information on chelation and details on performing large volume voluntary phlebotomy. The aim is to use evidence to support the successful management of this disorder to ensure optimal animal health, welfare, and longevity for a sustainable black rhinoceros population. Abstract: Critically endangered black rhinoceros (BR) under human care are predisposed to non-hemochromatosis Iron Overload Disorder (IOD).
    [Show full text]
  • Essentials of Medical Genetics for Health Professionals
    59605_Gunder_FM_00i_xii_3 8/27/10 12:58 PM Page i Essentials of Medical Genetics for Health Professionals Laura M. Gunder, DHSc, MHE, PA-C Assistant Professor Physician Assistant Department School of Allied Health Sciences Medical College of Georgia Augusta, Georgia Adjunct Faculty Doctor of Health Sciences Program Arizona School of Health Sciences A.T. Still University Mesa, Arizona Staff Clinician Peachtree Medical Center Edgefield County Hospital Ridge Spring, South Carolina Scott A. Martin, MS, PhD, PA-C Dean Life Sciences Division Athens Technical College Athens, Georgia Clinical Professor Physician Assistant Department School of Allied Health Sciences Medical College of Georgia Augusta, Georgia Staff Clinician Family Medicine Athens, Georgia 59605_Gunder_FM_00i_xii_3 8/27/10 12:58 PM Page ii World Headquarters Jones & Bartlett Learning Jones & Bartlett Learning Canada Jones & Bartlett Learning International 40 Tall Pine Drive 6339 Ormindale Way Barb House, Barb Mews Sudbury, MA 01776 Mississauga, Ontario L5V 1J2 London W6 7PA 978-443-5000 Canada United Kingdom [email protected] www.jblearning.com Jones & Bartlett Learning books and products are available through most bookstores and online booksellers. To contact Jones & Bartlett Learning directly, call 800-832-0034, fax 978-443-8000, or visit our website, www.jblearning.com. Substantial discounts on bulk quantities of Jones & Bartlett Learning publications are available to corporations, profes- sional associations, and other qualified organizations. For details and specific discount information, contact the special sales department at Jones & Bartlett Learning via the above contact information or send an email to [email protected]. Copyright © 2011 by Jones & Bartlett Learning, LLC All rights reserved. No part of the material protected by this copyright may be reproduced or utilized in any form, electronic or mechanical, including photocopying, recording, or by any information storage and retrieval system, without written permission from the copyright owner.
    [Show full text]
  • Ferriprox (Deferiprone) Tablets Contain 500 Mg Deferiprone (3-Hydroxy-1,2-Dimethylpyridin-4-One), a Synthetic, Orally Active, Iron-Chelating Agent
    HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use FERRIPROX safely and effectively. See full prescribing information for ------------------------------CONTRAINDICATIONS------------------------------- FERRIPROX. • Hypersensitivity to deferiprone or to any of the excipients in the FERRIPROX® (deferiprone) tablets, for oral use formulation. (4) Initial U.S. Approval: 2011 ------------------------WARNINGS AND PRECAUTIONS----------------------- WARNING: AGRANULOCYTOSIS/NEUTROPENIA • If infection occurs while on Ferriprox, interrupt therapy and monitor the See full prescribing information for complete boxed warning. ANC more frequently. (5.1) • Ferriprox can cause agranulocytosis that can lead to serious • Ferriprox can cause fetal harm. Women should be advised of the infections and death. Neutropenia may precede the development of potential hazard to the fetus and to avoid pregnancy while on this drug. agranulocytosis. (5.1) (5.3) • Measure the absolute neutrophil count (ANC) before starting Ferriprox and monitor the ANC weekly on therapy. (5.1) -----------------------------ADVERSE REACTIONS-------------------------------- • Interrupt Ferriprox if infection develops and monitor the ANC more frequently. (5.1) • The most common adverse reactions are (incidence ≥ 5%) chromaturia, • Advise patients taking Ferriprox to report immediately any nausea, vomiting and abdominal pain, alanine aminotransferase symptoms indicative of infection. (5.1) increased, arthralgia and neutropenia. (5.1, 6) -----------------------------INDICATIONS AND USAGE-------------------------- To report SUSPECTED ADVERSE REACTIONS, contact ApoPharma Inc. at: Telephone: 1-866-949-0995 FERRIPROX® (deferiprone) is an iron chelator indicated for the treatment of Email: [email protected] or FDA at 1-800-FDA-1088 or patients with transfusional iron overload due to thalassemia syndromes when www.fda.gov/medwatch current chelation therapy is inadequate. (1) Approval is based on a reduction in serum ferritin levels.
    [Show full text]
  • A Short Review of Iron Metabolism and Pathophysiology of Iron Disorders
    medicines Review A Short Review of Iron Metabolism and Pathophysiology of Iron Disorders Andronicos Yiannikourides 1 and Gladys O. Latunde-Dada 2,* 1 Faculty of Life Sciences and Medicine, Henriette Raphael House Guy’s Campus King’s College London, London SE1 1UL, UK 2 Department of Nutritional Sciences, School of Life Course Sciences, King’s College London, Franklin-Wilkins-Building, 150 Stamford Street, London SE1 9NH, UK * Correspondence: [email protected] Received: 30 June 2019; Accepted: 2 August 2019; Published: 5 August 2019 Abstract: Iron is a vital trace element for humans, as it plays a crucial role in oxygen transport, oxidative metabolism, cellular proliferation, and many catalytic reactions. To be beneficial, the amount of iron in the human body needs to be maintained within the ideal range. Iron metabolism is one of the most complex processes involving many organs and tissues, the interaction of which is critical for iron homeostasis. No active mechanism for iron excretion exists. Therefore, the amount of iron absorbed by the intestine is tightly controlled to balance the daily losses. The bone marrow is the prime iron consumer in the body, being the site for erythropoiesis, while the reticuloendothelial system is responsible for iron recycling through erythrocyte phagocytosis. The liver has important synthetic, storing, and regulatory functions in iron homeostasis. Among the numerous proteins involved in iron metabolism, hepcidin is a liver-derived peptide hormone, which is the master regulator of iron metabolism. This hormone acts in many target tissues and regulates systemic iron levels through a negative feedback mechanism. Hepcidin synthesis is controlled by several factors such as iron levels, anaemia, infection, inflammation, and erythropoietic activity.
    [Show full text]